Archive · 24 Jul 2026
PLI schemes attract ₹2.4 lakh crore investment
The Indian government has given out ₹35,354 crore to companies under the Production Linked Incentive (PLI) schemes.
These schemes, started in 2020, aim to boost manufacturing in 14 key sectors.
As of March 31, 2026, 892 applications have been approved, leading to investments of over ₹2.4 lakh crore.
This has resulted in the production and sale of goods worth ₹22.66 lakh crore, exports worth ₹15.2 lakh crore, and the creation of over 14.15 lakh jobs.
The pharmaceutical sector has seen significant growth, with the manufacture of 1,931 products, including 191 bulk drugs made in India for the first time.
The government has disbursed ₹35,354 crore under PLI schemes as of March 31, 2026.
PLI schemes have attracted investments of over ₹2.4 lakh crore across 14 sectors.
Approved applications have led to production and sales worth ₹22.66 lakh crore and exports worth ₹15.2 lakh crore.
Over 14.15 lakh jobs have been generated, including 8.4 lakh direct jobs.
The pharmaceutical sector has recorded cumulative sales of over ₹3.64 lakh crore and the manufacture of 1,931 products, including 191 bulk drugs made in India for the first time.
- Who
- Indian Government
- What
- Disbursement of ₹35,354 crore under PLI schemes
- When
- As of March 31, 2026
- Where
- India
- Why
- To enhance manufacturing capabilities, attract investments, promote exports, generate employment, and reduce import dependence
Government Perspective
Industry Perspective
Effectiveness of PLI Schemes
Government Perspective
The government believes the PLI schemes have successfully attracted significant investments and boosted manufacturing capabilities.
Industry Perspective
Industry representatives may argue that the incentives could be higher to achieve even greater growth and employment.
- Total Investment
- ₹2.4 lakh crore
- Incentives Disbursed
- ₹35,354 crore
- Approved Applications
- 892
- Sectors Covered
- 14
- Employment Generated
- 14.15 lakh (direct and indirect)
- Pharmaceutical Sales
- ₹3.64 lakh crore
- New Pharmaceutical Products
- 1,931
- First-Time Manufactured Bulk Drugs
- 191